Bombesin Peptide Helps Guide Green Tea Compound Directly to Breast Cancer Cells via Nanoparticles

The researchers prepared solid lipid nanoparticles loaded with EGCG using standard nanoparticle fabrication techniques. Bombesin peptide was conjugated to the nanoparticle surface to enable targeting of GRPR-overexpressing cancer cells. In vitro cytotoxicity was assessed on cancer cell lines. In vivo efficacy was evaluated in C57/BL6 mice bearing breast tumors, measuring tumor volume and survival over the treatment period.

EGCG has well-documented anticancer properties but is limited by poor stability and bioavailability in the body. Using a peptide like bombesin to guide drug-loaded nanoparticles directly to tumor cells is a strategy that could dramatically improve the therapeutic index of natural anticancer compounds — delivering more drug to the tumor while reducing off-target effects.

Peptide-targeted nanoparticle drug delivery is a rapidly growing field in cancer research. Bombesin and other tumor-homing peptides offer advantages over antibody-based targeting due to their smaller size, lower immunogenicity, and easier synthesis. This study adds to the evidence that peptide-guided delivery can enhance the efficacy of natural compounds that would otherwise have limited clinical utility due to poor pharmacokinetics.

The study used a single mouse strain and breast tumor model, which may not capture the diversity of human breast cancers. Specific tumor volume measurements and survival data were not provided in the abstract. The pharmacokinetics, biodistribution, and long-term safety of the bombesin-conjugated nanoparticles were not detailed. EGCG doses used in nanoparticle form may not directly translate to human therapeutic doses.